In April of 2013, the Canadian Diabetes Association (CDA) published its 5th iteration of the Clinical Practice Guidelines (CPG) for the Prevention and Management of Diabetes in Canada (available at http://guidelines.diabetes.ca/) [1]. These guidelines were developed with the same methodologic rigor and transparency as the previous version which has garnered recognition for its high quality among international diabetes guidelines [2]. Within its 38 chapters are sections on diabetes screening, diagnosis, and monitoring which rely heavily on laboratory testing. There are some important changes from the 2008 CDA CPGs that may impact the volume of tests seen in the clinical laboratory, and others which may impact reporting or interpretation of results. This article will highlight those changes in addition to notable items that have not changed, as well as some differences from other international guidelines.
展开▼
